TCT 2019 | EXCEL: Left Main Coronary Artery Angioplasty with Favorable Results at 5 Years

Courtesy of Dr. Carlos Fava.

Unprotected left main coronary artery angioplasty with drug-eluting stents has emerged as an acceptable strategy for a select group of patients, with results comparable to those of myocardial revascularization surgery at 2 or 3 years. However, beyond such term, we had no valid information.

Highlights TCT 2019

Researchers analyzed the 5-year follow-up results for the EXCEL trial, which randomized 948 patients with an intermediate or low SYNTAX score to undergo angioplasty with an everolimus-eluting stent (XIENCE, Abbott Vascular) while others were randomized to coronary artery revascularization surgery.

The primary endpoint at 5 years consisted of death, stroke, or infarction, while the secondary endpoint at 5 years was a composite of death, stroke, infarction, and ischemia-driven revascularization.

Groups were similar: the mean age was 66 years old, most patients were male, and 30% of subjects had diabetes. The SYNTAX score was 20.6 ± 6.2 for local sites and 26.5 ± 6.3 for core lab with angiography. About 80.5% of patients had severe bifurcation lesion in the left main coronary artery.


Read also: TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS.


Over 90% of patients in both groups completed the 5-year follow-up. There were no differences in the primary endpoint (22% for angioplasty and 19.2% for myocardial revascularization surgery; p = 0.13). The secondary endpoint favored myocardial revascularization surgery (24.1% vs. 31.2%; p = 0.002), driven by a higher need for ischemia-driven revascularization (16.9% vs. 10%; p > 0.001). There were no differences as regards cardiac death, infarction, or stroke. Non-cardiac death rates were higher in the angioplasty group.

Conclusion

In patients with unprotected left main coronary artery disease who had intermediate or low anatomical complexity, there were no differences between angioplasty and myocardial revascularization surgery as regards death, stroke, or infarction after a 5-year follow-up.

Courtesy of Dr. Carlos Fava.

Link to the SBHCI Publication HERE

excel

excel-5yearpdf

Original Title: EXCEL: 5-Year Outcomes From a Randomized Trial of PCI vs. CABG in Patients With Left Main Coronary Artery Disease.

Author of the Original Title: Gregg W. Stone.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...